|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | PhaseI pharma- cokinetie and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand recep- tor显示文摘 | Tolcher AW Mita M Meropol NJ etal | 2007 | J Clin Oncol2007，25，： | 1 |
| 2 | Novel therapeutic molecular targets for prostate cancer: the roTOR signaling pathway and epidermal growth factor receptor 显示文摘 | Tolcher AW | 2004 | J Urol2004，171，2： | 1 |
| 3 | Phase I pharmacokinetic and biologic correlative study of mapatumumab,a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1显示文摘 | Tolcher AW Mita M Meropol NJ | 2007 | J Clin Oncol2007，25，11： | 1 |
| 4 | Technology insight: cytotoxic drug immunoconjugates for cancer therapy 显示文摘 | Ricart AD Tolcher AW | 2007 | Nat Clin Pract Oncol2007，4，4： | 1 |
| 5 | ONX 0912,a Novel Oral Proteasome Inhibitor (PI) ,In Patients (pts) With Advanced Re- fractory or Recurrent Solid Tumours : a Phase 1, O-pen - label, Dose Escalation Study显示文摘 | Papadopoulos K Mendelson D Tolcher AW et at | 2011 | European Journal of cancer2011，471，： | 1 |
| 6 | Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules 显示文摘 | Tolcher AW Gerson SL Denis L | 2003 | Br J Cancer2003，88，7： | 1 |
| 7 | Phase I , pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor l 显示文摘 | Tolcher AW Sarantopoulos J Patnaik A | 1997 | J Clin Oncol1997，27，34： | 1 |
| 8 | Phase I study of RO4929097,a gamma secretase inhibitor of Notch signaling,in patients with refractory metastatic or locally advanced solid tumors显示文摘 | Tolcher AW Messersmith WA Mikulski SM | 2012 | J Clin Oncol2012，30，19： | 1 |
| 9 | A phase I and biologic correlative study of an oral endothelial vascular growth factor receptor-2(VEGFR-2) tyrosine kinase inhibitor,CP-547,632 in patients with advanced solid tumors显示文摘 | Tolcher AW O'Leary J DeBono JS | 2002 | Proc ASCO2002，21，： | 1 |
| 10 | The role of mTOR inhibitors for treatment of sarcomas显示文摘 | Mita MM Tolcher AW | 2007 | Curt Oncol Rep2007，9，4： | 1 |
| 11 | Marked inactivation of O-6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules 显示文摘 | Tolcher AW Gerson SL Denis L | 2003 | Br J Cancer2003，88，7： | 1 |
| 12 | Volociximab,a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin:a phase Ⅰ,pharmacokinetic,and biological correlative study显示文摘 | Ricart AD Tolcher AW Liu G | | 0，，23： | 1 |
| 13 | Phase I , pharmacokinetic, and DCE-MRI correlative study of AVES062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days 显示文摘 | Tolcher AW Forero L Celio P | 2003 | J Clin Oncol2003，，： | 1 |
| 14 | Phase I study of RO4929097, a gamma secretase inhibitor of Notch signalinl, in patients with refractory metastatic or locally advanced solid tumors显示文摘 | Tolcher AW Messersmith WA Mikulski SM | 2012 | J Clin Oncol2012，30，19： | 1 |
| 15 | Phase I ,pharmacokinetic, and pharmacodynamic study of AMG 479, a fullyhuman monoclonal antibody to insulin-like growth factor receptor 1显示文摘 | Tolcher AW Saiantopoulos J Patnaik A | 2009 | J Clin Oncol2009，27，34： | 1 |
| 16 | Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor 显示文摘 | Tolcher AW | 2004 | J Urol2004，171，22： | 1 |
| 17 | A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors 显示文摘 | Tolcher AW | 2006 | J Clin Oncol2006，24，： | 1 |
| 18 | Phase I dose -escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors显示文摘 | SHIMIZU T TOLCHER AW PATNAIK A | 2010 | J Clin Oncol2010，28，15： | 1 |
| 19 | Con- tinuous -dose regorafenib (REG) in hepatocellular carcino- ma (HCC) : Phase I safety and pharmacokinetic (PK) study 显示文摘 | FINN RS BLUMENSCHEIN GR TOLCHER AW | 2013 | J Clin Oncol2013，31，4： | 1 |
| 20 | A phaseⅡstudy of YM155,a novel smallmolecule suppressor of survivin,in castration-resistant taxanepretreated显示文摘 | Tolcher AW Quinn DI | 2012 | Annals of Oncology2012，23，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员